Ken Bartizal is Chief Development Officer at Trius Therapeutics Inc (TSRX). They have made 1 open-market trade across 1 company since 2011, most recently 2013-09-11.
CIK 0001478832
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TSRX | 95,300 | — |
Shares reported on the most recent Form 4, priced at the 2013-07-01 close. 1 holding could not be priced and is excluded from the total.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TSRX | SELL · 10b5-1 | 2013-07-01 | 2013-07-01 | $8.14 | $16K | N/A | N/A | N/A |
| TSRX | SELL · 10b5-1 | 2013-06-04 | 2013-06-04 | $7.90 | $16K | N/A | N/A | N/A |
| TSRX | SELL · 10b5-1 | 2013-05-24 | 2013-05-28 | $7.93 | $95K | N/A | N/A | N/A |
| TSRX | SELL | 2013-05-14 | 2013-05-28 | $7.85 | $94K | N/A | N/A | N/A |
| TSRX | SELL · 10b5-1 | 2011-11-17 | 2011-11-18 | $7.85 | $13K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.